FDA approval of Eli Lilly’s oral obesity pill Foundayo set up an immediate competitive face-off with Novo Nordisk’s oral Wegovy strategy. Analysts framed the market impact around differences in clinical outcomes, dosing logistics, and the absence of true head-to-head trials. Lilly’s Phase 3 ATTAIN-1 trial data supported Foundayo’s weight-loss results, while Novo’s OASIS 4 program underpins Wegovy’s performance claims. Novo is positioning the pill’s comparative benefits via a simulated treatment comparison and related messaging on label and dosing constraints. For the sector, the key near-term watch items are script momentum, adherence in real-world settings, payer coverage, and whether the next comparative datasets narrow uncertainty around relative efficacy and tolerability for specific patient segments.